11 |
2-ME-induced apoptotic signalling in prostate cancer PC3 cells /Davoodpour, Padideh, January 2005 (has links)
Diss. (sammanfattning) Uppsala : Uppsala universitet, 2005. / Härtill 3 uppsatser.
|
12 |
Prostate cancer and inflammatory genes /Lindmark, Fredrik, January 2005 (has links)
Diss. (sammanfattning) Umeå : Univ., 2006. / Härtill 4 uppsatser.
|
13 |
Prediction of survival in prostate cancer : aspects on localised, locally advanced and metastatic disease /Robinson, David, January 2008 (has links) (PDF)
Diss. (sammanfattning) Linköping : Linköpings universitet, 2008. / Härtill 5 uppsatser.
|
14 |
Ein Beitrag zum Problem des Prostata-Carcinoms unter besonderer Berücksichtigung der occulten KrebseHerb, Ernst, January 1955 (has links)
Thesis (doctoral)--Würzburg, 1955. / Includes bibliographical references (p. 41-43).
|
15 |
Ein Beitrag zum Problem des Prostata-Carcinoms unter besonderer Berücksichtigung der occulten KrebseHerb, Ernst, January 1955 (has links)
Thesis (doctoral)--Würzburg, 1955. / Includes bibliographical references (p. 41-43).
|
16 |
The psychometric evaluation of the Chinese version of the international prostate symptom score (IPSS)Chan, Hin-cheong. January 2004 (has links)
Thesis (M.Nurs.)--University of Hong Kong, 2004. / Also available in print.
|
17 |
Dual regulation of telomerase activity by HSF1 and its role in prostate cancer progression /Jensen, Keith Douglas Ostergaard, January 2006 (has links)
Thesis (Ph. D.)--Virginia Commonwealth University, 2006. / Prepared for: Dept. of Human Genetics. Bibliography: leaves [112] - 124. Also available online.
|
18 |
Efeitos da toxina botulínica do tipo A isolada ou em associação com a finasterida sobre a próstata do cão e rato Sprague-DawleyMostachio, Giuliano Queiroz [UNESP] 10 February 2012 (has links) (PDF)
Made available in DSpace on 2014-06-11T19:31:08Z (GMT). No. of bitstreams: 0
Previous issue date: 2012-02-10Bitstream added on 2014-06-13T19:20:09Z : No. of bitstreams: 1
mostachio_gq_dr_jabo.pdf: 1264077 bytes, checksum: 8bcdd5ff1f9b2ceba2b78fb1998b3095 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, no entanto, sua fisiopatologia não está totalmente compreendida. O objetivo principal do tratamento da HPB é controlar o crescimento do órgão, prevenir complicações e efeitos colaterais. Desta maneira, o efeito da toxina botulínica tem sido investigado, mostrando bons resultados no homem. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da finasterida e da TB-A no tratamento da HPB canina. Para tanto, 24 cães adultos foram divididos aleatoriamente em quatro grupos e submetidos à administração de solução fisiológica 0,9%, 5 mg de finasterida, 500 U de TB-A ou 500 U de TB-A associada a finasterida, e avaliados durante 16 semanas. Complicações locais ou alterações sistêmicas não foram observadas nos animais pertencentes aos grupos experimentais. Após 16 semanas da administração de 5 mg de finasterida o volume prostático reduziu 45,3% e ocorreu um aumento de 5 vezes nas taxa de morte celular. Comparando-se os valores do volume prostático após 16 semanas da aplicação de 500 U de TB-A ou 500 U de TB-A associada a finasterida com os valores basais, observamos uma redução de 30,9 e 51,3%, respectivamente. Neste mesmo período, ocorreu um aumento de seis e oito vezes da taxa de apoptose nos animais do grupo III e IV. Os resultados sugerem que os três protocolos terapêuticos promovem significativa redução do volume prostático e esta se deve a apoptose celular ao invés de necrose. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina / Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 – 2 years, however, its pathophysiology is not fully elucidated. The main goal of BPH is to control the growth of the prostate, to prevent complications, and to minimize the adverse effects. Thus, the effect of botulinum toxin A (BT-A) has been investigated in humans with good results. Based on that, this study aimed to provide information about the effects of finasteride and BT-A in the treatment of BPH in dogs. For that, 24 adults dogs were randomly divided in four groups and submitted to administration of saline solution, 5 mg of finasteride, 500 of BT-A or 500 U of BT-A associated with finasteride, and evaluated along 16 weeks. Local complications and systemic effects were not observed. After 16 weeks of the application of 5 mg of finasteride the prostatic volume decreased 45,3% and occurred a 5-fold increased in the rate of cell death. Comparing the values of the prostatic volume after 16 weeks of administration of 500 U of BT-A or 500 U BT-A associated with finasteride with the baseline, a decrease of 30,9 and 51,3% were observed, respectively. In the same period, a increase of 6 and 8 times occurred in the rate of apoptosis in the animals of group III and IV. The results suggest that all 3 treatments protocols further significant reduction in the prostate volume have shown to significantly reduce the volume of prostate, and this reduction is due apoptosis instead necrosis. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate
|
19 |
MR imaging biomarkers for benign prostatic hyperplasia pharmacotherapyJia, Guang, January 2006 (has links)
Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 87-93).
|
20 |
Evaluating diagnostic and treatment modalities in the management of benign prostatic hyperplasia in the Veterans Administration populationFernandes, Ancilla W. January 2000 (has links)
Thesis (M.S.)--West Virginia University, 2000. / Title from document title page. Document formatted into pages; contains ix, 154 p. : ill. Includes abstract. Includes bibliographical references (p. 137-143).
|
Page generated in 0.0534 seconds